Answers are grounded in this paper and cite their sources.
Objective. To perform a 5-year (2016–2020) monitoring of data from the register of children with juvenile idiopathic arthritis (JIA) in Moscow. Patients and methods. We conducted an observational, descriptive, cross-sectional study involving 1220 JIA patients aged 0 to 17 years. The sample included 783 girls (64.2%) and 437 boys (35.8%). Results. We found that the prevalence of JIA among children aged 0–17 years in Moscow doubled over the last 5 years: from 28.7 to 55.8 per 100,000. There was a minor increase in the primary incidence of JIA: from 9.5 to 12.5 per 100,000. There were some changes in the JIA structure, including a 7% reduction in the proportion of polyarticular seronegative JIA and an 8.3% reduction in the proportion of systemic JIA, along with an 19.4% increase in the proportion of oligoarticular JIA. We observed no significant differences in the structure of basic anti-inflammatory therapy. Approximately 80% of patients received basic therapy; the drug of choice was methotrexate (86.9%). Tumor necrosis factor-α inhibitors (such as etanercept, adalimumab, and golimumab) were the most commonly used biologicals. The frequency of etanercept use increased from 44.9% to 50.7% over 5 years. Conclusion. Regional registers of patients with rheumatic diseases are the most important tool for surveillance, assessment of JIA structure, course, and comorbidities, identification of patients at risk for disability, planning pharmacotherapy, and calculating its cost.
No takes yet. Share an insight, caveat, or question.
Sevostyanov et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: